Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes. The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects With Acute Coronary Syndrome)

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes. The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects With Acute Coronary Syndrome)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Thienopyridines
  • Indications Acute coronary syndromes; Cardiovascular disorders; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATLAS-ACS-TIMI-46
  • Sponsors Bayer

Most Recent Events

  • 18 Nov 2019 Results (N= 1282), post-hoc analysis to assess the link between WBC count and bleeding in patients on Rivaroxaban, presented at the American Heart Association Scientific Sessions 2019
  • 14 Nov 2018 Results assessing the association between D-Dimer Levels and Clinical Outcomes in Acute Coronary Syndrome Patients (n=1,834) presented at the 91st Annual Scientific Sessions of the American Heart Association
  • 04 Aug 2018 Results of a substudy in a subset of subjects (n =1834) assessing the D-dimer levels and the effect of Rivaroxaban on those levels and outcomes in patients with acute coronary syndrome, published in the American Journal of Cardiology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top